The World’s First Rapid and Effective Ingestible Nicotine Delivery Technology

Welcome to Lexaria Nicotine Corp.

Lexaria Nicotine Corp. is the exclusive worldwide provider of the Dehydratech drug delivery technology for the nicotine industry, licensed from our parent Lexaria Bioscience Corp.

Lexaria’s DehyraTECH drug delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of lipophilic molecules such as nicotine.

Learn More

About DehydraTECH

Lexaria’s patented technology, DehydraTECH™ delivers these important benefits upon oral ingestion:

Masks taste/odor

Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners.

Reduces time of onset

In animal tests, nicotine measured in blood plasma in as little as 2 minutes.

Avoids first-pass liver metabolism

Initial testing indirectly evidences DehydraTECH™ may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects.

Increases bio-absorption

Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.

Lexaria’s disruptive new technology DehydraTECH can be licensed to improve existing nicotine products or create revolutionary new ones.

The technology behind the products

Lexaria’s DehydraTECH

Learn More

Latest News